Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Do you value companies holding large amounts of cash? For a closer look at highly liquid names, we ran a screen on the healthcare sector.

We began by screening U.S.-traded healthcare stocks for those with significant liquidity, with current ratios above 3. Since the current ratio is current assets/current liabilities, a ratio of 3 or more indicates the company has liquid assets at least three times their short-term liabilities.

We then screened these names for those with strong value, by finding those that appear undervalued relative to EPS Trends. Based on the assumption that P/E is equal to a constant k, increases in EPS should be matched by increases in price. When they don't match up, a mispricing may have occurred.

We screened for stocks with faster growth in EPS estimates than price over the last month, which may indicate that these names are being undervalued.

Interactive Chart: Press Play to compare changes in market cap over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.

Do you think these names hold solid value? Use this list as a starting point for your own analysis.

List sorted by difference between change in EPS and price over the last 30 days.

1. Mesa Laboratories Inc. (MLAB): Designs, manufactures and markets instruments and disposable products utilized primarily in healthcare, pharmaceutical, food and beverage, medical device and petrochemical industries. Market cap at $166.01M. Price at $50.24. Current ratio at 3.77. The EPS estimate for the company's current year increased from 2.02 to 2.33 over the last 30 days, an increase of 15.35%. This increase came during a time when the stock price changed by 8.38% (from 46.3 to 50.18 over the last 30 days).

2. Acorda Therapeutics, Inc. (ACOR): Involves in the identification, development and commercialization of therapies for multiple sclerosis, spinal cord injury and other nervous system disorders. Market cap at $963.52M. Price at $24.45. Current ratio at 4.13. The EPS estimate for the company's current year increased from 0.4 to 0.43 over the last 30 days, an increase of 7.5%. This increase came during a time when the stock price changed by -10.38% (from 27.06 to 24.25 over the last 30 days).

3. Almost Family Inc. (AFAM): Provides home health services in the United States. Market cap at $223.12M. Price at $24.45. Current ratio at 3.22. The EPS estimate for the company's current year increased from 1.87 to 1.88 over the last 30 days, an increase of 0.53%. This increase came during a time when the stock price changed by -6.77% (from 25.7 to 23.96 over the last 30 days).

4. SciClone Pharmaceuticals, Inc. (SCLN): Engages in the development and commercialization of novel therapeutics for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders in the People's Republic of China and internationally. Market cap at $375.45M. Price at $6.49. Current ratio at 4.79. The EPS estimate for the company's current year increased from 0.66 to 0.71 over the last 30 days, an increase of 7.58%. This increase came during a time when the stock price changed by 0.62% (from 6.45 to 6.49 over the last 30 days).

5. 3SBio Inc. (SSRX): Engages in the research, development, manufacture and distribution of pharmaceutical products in the People's Republic of China. Market cap at $289.12M. Price at $13.14. Current ratio at 15.54. The EPS estimate for the company's current year increased from 0.94 to 0.97 over the last 30 days, an increase of 3.19%. This increase came during a time when the stock price changed by -3.78% (from 13.77 to 13.25 over the last 30 days).

6. Gilead Sciences Inc. (GILD): Engages in the discovery, development and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Market cap at $34.77B. Price at $46.66. Current ratio at 5.53. The EPS estimate for the company's current year increased from 3.83 to 3.84 over the last 30 days, an increase of 0.26%. This increase came during a time when the stock price changed by -3.31% (from 47.07 to 45.51 over the last 30 days).

7. Harvard Bioscience Inc. (HBIO): Develops, manufactures and markets apparatus and scientific instruments used in life science research in pharmaceutical and biotechnology companies, universities and government laboratories in the United States and internationally. Market cap at $116.44M. Price at $4.06. Current ratio at 6.02. The EPS estimate for the company's current year increased from 0.29 to 0.3 over the last 30 days, an increase of 3.45%. This increase came during a time when the stock price changed by 1.81% (from 3.87 to 3.94 over the last 30 days).

8. Impax Laboratories Inc. (IPXL): Engages in the development, manufacture and marketing of bioequivalent pharmaceutical products. Market cap at $1.58B. Price at $24.99. Current ratio at 3.82. The EPS estimate for the company's current year increased from 1.83 to 1.85 over the last 30 days, an increase of 1.09%. This increase came during a time when the stock price changed by -0.72% (from 23.77 to 23.6 over the last 30 days).

*EPS data sourced from Yahoo! Finance, all other data sourced from Finviz.

Source: 8 Highly Liquid Healthcare Stocks Undervalued By EPS Trends